Specify Company / Ticker to Get the Summary
Dividend History IMVT
Dividend Analytics IMVT
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Immunovant Inc
IMVTImmunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. Address: 320 West 37th Street, New York, NY, United States, 10018
Analytics
WallStreet Target Price
43.38 USDP/E Ratio
–Dividend Yield
–Financials IMVT
Results | 2019 | Dynamics |